Ping Identity (PING) Announces 6M Share Offering by Selling Stockholders

Ping Identity Holding Corp. (NYSE: PING) the Intelligent Identity solution for the enterprise, today announced the commencement of an underwritten public offering of 6,000,000 shares of common stock by investment funds affiliated with Vista Equity Partners. Such selling stockholders will also grant the underwriters a 30-day option to purchase up to an additional 900,000 shares of Ping Identity’s common stock. Ping Identity will not receive any of the proceeds from the sale of the shares being offered by the selling stockholders but will bear the costs associated with the sale of such shares, other than underwriting discounts and commissions.

Morgan Stanley is acting as sole underwriter for the proposed offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.

A registration statement on Form S-3 relating to these securities has been filed with the Securities and Exchange Commission (“SEC”) and has become effective. The proposed offering will be made only by means of a prospectus and a free writing prospectus. A copy of the prospectus and the free writing prospectus relating to this offering may be obtained, when available, by visiting the SEC’s website at www.sec.gov or by contacting the offices of Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any offer or sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

You May Also Be Interested In

• Aggreko files for NYSE IPO under ticker AGKO
• Oruka Therapeutics names Todd Edwards as chief commercial officer
• Alkermes narcolepsy drug data published in The Lancet Neurology